Vall d'Hebron Institute of Oncology

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM

  NCT07867886· Boston Scientific Corporation· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· SystImmune Inc.· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Not yet recruiting

  Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

  NCT07013851· Phase 2· Grupo Español de Investigación en Cáncer de Ovario· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

• Recruiting

  Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

  NCT07151040· Phase 1/2· One-carbon Therapeutics AB· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  NCT07020221· Phase 1/2· Verastem, Inc.· Source

• Recruiting

  Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

  NCT06960577· Phase 2· AstraZeneca· Source

• Recruiting

  Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

  NCT06630611· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  NCT06534983· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)

  NCT06435429· Phase 3· Jazz Pharmaceuticals Ireland Limited· Source

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Institut de Recherches Internationales Servier· Source

• Recruiting

  A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated by the Body and How the Body Absorbs, Distributes, Metabolizes and Excretes ZL-1310

  2024-514446-36-00· Phase 1· Zai Lab (US) LLC· Source

• Recruiting

  The Sagittarius Trial

  NCT06490536· Phase 3· IFOM ETS - The AIRC Institute of Molecular Oncology· Source

• Active, not recruiting

  POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE PEGASUS STUDY

  NCT04259944· Phase 2· IFOM Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source

• Active, not recruiting

  DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

  NCT06132113· Phase 1· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

  NCT06868355· University of Manchester· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

  NCT05822752· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  NCT05683418· Phase 1· Totus Medicines· Source

• Recruiting

  Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

  NCT05916755· Vall d'Hebron Institute of Oncology· Source

• Recruiting

  A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  NCT05592626· Phase 1/2· Marengo Therapeutics, Inc.· Source

• Recruiting

  Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

  NCT05751798· Phase 1/2· OSE Immunotherapeutics· Source

• Active, not recruiting

  Single cEll pRofiling PErsistaNce To ImmuNothErapy

  NCT06680739· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Recruiting

  I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

  NCT05537922· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source

• Recruiting

  SPRING Rollover

  2022-500041-24-00· Phase 1/2· Worldwide Innovative Network· Source

• Recruiting

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· Phase 1· Relay Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

  NCT04958239· Phase 1· Boehringer Ingelheim· Source

• Recruiting

  Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

  NCT04657822· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  NCT04657068· Phase 1/2· Artios Pharma Ltd· Source

• Recruiting

  A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)

  NCT05101382· IFOM ETS - The AIRC Institute of Molecular Oncology· Source

• Recruiting

  BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

  NCT04421820· Phase 1/2· Bold Therapeutics, Inc.· Source

• Active, not recruiting

  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

  NCT04561362· Phase 1/2· BicycleTx Limited· Source

• Recruiting

  A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  NCT04389632· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

  NCT04300244· Phase 2· Åslaug Helland· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  NCT04191499· Phase 2/3· Hoffmann-La Roche· Source

• Active, not recruiting

  Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

  2022-502604-67-00· Phase 2/3· Oslo University Hospital Hf· Source

• Active, not recruiting

  Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

  NCT04140500· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  ALFAOMEGA Master Observational Trial

  NCT04120935· IFOM ETS - The AIRC Institute of Molecular Oncology· Source

• Recruiting

  Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

  NCT04832607· Phase 3· Tobias Feuchtinger· Source

• Active, not recruiting

  Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

  NCT03979131· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source

• Active, not recruiting

  A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 54.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer10 recruiting
• Colorectal cancer9 recruiting
• Endometrial cancer5 recruiting
• Head and neck cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Gastric and oesophageal cancer4 recruiting
• Pancreatic cancer4 recruiting
• Bladder cancer3 recruiting
• Cervical cancer3 recruiting
• Childhood cancers3 recruiting
• Kidney cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Melanoma2 recruiting
• Ovarian cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Cytomegalovirus infection1 recruiting
• Glioblastoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

  2024-512670-10-00· Phase 1/2· BioInvent International AB· Source

• Completed

  EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer

  NCT05075577· Phase 1/2· Essa Pharma Inc.· Source

• Completed

  HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

  NCT05865990· Phase 2· MedSIR· Source

• Completed

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

  NCT06403436· Phase 1· TOLREMO therapeutics AG· Source

• Terminated

  A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

  NCT05619172· Phase 2· SOTIO Biotech AG· Source

• Completed

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  2022-500652-37-00· Phase 2· Agenus Inc.· Source

• Completed

  A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

  NCT05187624· Phase 1· Hoffmann-La Roche· Source

• Completed

  Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

  NCT04826003· Phase 1· Hoffmann-La Roche· Source

• Terminated

  A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

  NCT04832854· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

  NCT04731467· Phase 1/2· Famewave Ltd.· Source

• Completed

  Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

  NCT04641871· Phase 1· Symphogen A/S· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  NCT04225715· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Hoffmann-La Roche· Source

• Completed

  A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

  2023-509463-24-01· Phase 2· Amsterdam UMC· Source

• Terminated

  A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

  NCT03901469· Phase 2· Zenith Epigenetics· Source

• Terminated

  Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

  NCT04234113· Phase 1· SOTIO Biotech AG· Source

• Completed

  Advanced GC Multi-omic Characterization in EU and CELAC Populations

  NCT04015466· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  NCT03869190· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

  NCT03748186· Phase 1· Sutro Biopharma, Inc.· Source

• Completed

  A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

  NCT03708328· Phase 1· Hoffmann-La Roche· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

  NCT03289962· Phase 1· Genentech, Inc.· Source

• Completed

  Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  NCT03037385· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

  NCT02508467· Phase 1· Blueprint Medicines Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer102 works · 25 trials
• Colorectal cancer73 works · 18 trials
• Metastatic breast cancer42 works · 8 trials
• Kidney cancer34 works · 7 trials
• Neuroendocrine tumours18 works · 3 trials
• Myeloproliferative neoplasms10 works · 1 trial
• Chronic lymphocytic leukaemia10 works · 1 trial
• Myelodysplastic syndromes9 works · 1 trial